Clinical trials
Breast Neoplasms trials in Serbia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 6 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Terminated | 7 |
| Active, not recruiting | 5 |
| Recruiting | 4 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 11 |
| Pfizer | 4 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Puma Biotechnology, Inc. | 3 |
| Amgen | 2 |
| AstraZeneca | 2 |
| Novartis Pharmaceuticals | 2 |
| University of Belgrade | 2 |
| Aileron Therapeutics, Inc. | 1 |
| Central European Cooperative Oncology Group | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 46 |
| Neoplasm Metastasis | 2 |
| Alopecia | 1 |
| Colonic Neoplasms | 1 |
| Infertility | 1 |
| Neoplasms | 1 |
| Neutropenia | 1 |
| Recurrence | 1 |
| Sexual Dysfunction, Physiological | 1 |
| Stomach Neoplasms | 1 |
Trials
Showing 1 to 25 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.